Novel approaches for the prevention of restenosis

Bibliography

• DOTTER CT, JUDKINS MP: Transluminal treatment ofarteriosclerotic obstruction: description of a new technique and a preliminary report of its application. Circulation (1964) 30:654–663.
   PubMed Web of Science ®Google Scholar
• GRUENTZIG AR, SENNING A, SIEGENTHALER WE: Non-operative dilatation of coronary artery stenosis - percutaneous transluminal coronary angioplasty. N Engl. J. Med. (1979) 301:61–69.
   PubMed Web of Science ®Google Scholar
• GRUENTZIG AR, KUMPE DA: Technique of percuta-neous transluminal angioplasty with the Gruentzig balloon catheter. AJR (1979) 132:547–552.
   PubMed Web of Science ®Google Scholar
• KUNTZ RE, BAIM DS: Prevention of coronary restenosis. The evolving evidence base for radiation therapy. Circulation (2000) 101:2130–2133.
   Google Scholar
• NOBUYOSHI M, KIMURA T, NOSAKA H et al.: Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J. Am. Coll Cardiol (1988) 12:616–623.
   PubMed Web of Science ®Google Scholar
• SERRUYS PW, LUITJEN HE, BEAEE KJ et al.: Incidence of restenosis after successful coronary angioplasty: a time related phenomenon: a quantitative angiographic study in 342 consecutive patients at 1,2, 3 and 4 months. Circulation (1988) 77:361–371.
   PubMed Web of Science ®Google Scholar
• LEINGRUBERG PP, ROUBIN GS, HOLLMAN J et al.: Restenosis after successful coronary angioplasty in patients with single vessel disease. Circulation (1986) 73:710–717.
   PubMed Web of Science ®Google Scholar
• HOLMES DR, VLIETSTRA RE, SMITH HC et al.: Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Institutes of Heart, Lung and Blood Institute. Am. J. Cardiol (1984) 53:77C–81C.
   Google Scholar
• SERRUYS PW, DE JAEGERE P, KIEMENEIJ F et al. (FOR THE BENESTENT STUDY GROUP): A comparison of balloon-expandable-stent implantation with angioplasty in patients with coronary artery disease. N Engl. J. Med. (1994) 331:489–495.
   PubMed Web of Science ®Google Scholar
• FISCHMAN DL, LEON MB, BAIM DS et al. (FOR THE STENT RESTENOSIS STUDY INVESTIGATORS): A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl. J. Med. (1994) 331:496–501.
   PubMed Web of Science ®Google Scholar
• KUNTZ RE, GIBSON CM, NOBUYOSHI M et al.: General-ized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. Am. Coll. Cardiol. (1993) 21:15–25.
   PubMed Web of Science ®Google Scholar
• CARROZA JP, JR, KUNTZ RE, SCHATZ RA et al.: Inter-series differences in the restenosis rate of Palmaz-Schatz coronary stent placement: differences in demographics and post-procedure lumen diameter. Cathet. Cardiovasc. Diagn. (1994) 31:173–178.
   PubMedGoogle Scholar
• COHEN DJ, KRUMHOLTZ HM, SUKIN CA et al.: In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty; results from a randomized clinical trial: Stent Restenosis Study Investigators. Circulation (1995) 92:2480–2487.
   PubMed Web of Science ®Google Scholar
• COLOMBO A, HALL P, NAKAMURA S et al.: Intracoronary stenting without anticoagulation accomplished with in tr avascular ultrasound guidance. Circulation (1995) 91:1676–1688.
   PubMed Web of Science ®Google Scholar
• LEON MB, BAIM DS, POPMA JJ et al.: A clinical trialcomparing three antithrombotic-drug regimens after coronary stenting. N Engl. J. Med. (1998) 339:1665–1671.
   PubMed Web of Science ®Google Scholar
• ALBIERO R, HALL P, ITOH A et al.: Results of a consecu-tive series of patients receiving only antiplatelet therapy after optimized stent implantation: comparison of aspirin alone versus combined ticlopidine and aspirin therapy. Circulation (1997) 95:1145–1156.
   PubMed Web of Science ®Google Scholar
• NARINS CR, HOLMES DR, JR., TOPOL EJ: A call forprovisional stenting. The balloon is back. Circulation (1998) 97:1298–1305.
   Google Scholar
• MINTZ GS, POPMA GS, PICHARD AD et al.: Arterialremodeling after coronary angioplasty: A serial intravascular ultrasound study. Circulation (1996) 77:1115–1118.
   Google Scholar
• GORDON PC, GIBSON CM, COHEN DJ et al.: Mechanismsof restenosis and redilation within coronary stents: quantitative angiographic assessment. J. Am. Coll. Cardiol. (1993) 21:1166–1174.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ RS, MURPHY JG, EDWARDS WD et al.: Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation (1990) 82:2190–2200.
   PubMed Web of Science ®Google Scholar
• KIMURA T, NOSAKA H, YOKOI H et al.: Serial angiographic follow-up after Palmaz-Schatz stent implantation: comparison with conventional balloon angioplasty. J. Am. Coll. Cardiol. (1999) 21:1557–1563.
   Google Scholar
• KASTRATI A, SCHOMIG A, DIETZ R et al.: Time course of restenosis during the first year after emergency coronary stenting. Circulation (1993) 87:1498–1505.
   PubMed Web of Science ®Google Scholar
• GARRATT KN, EDWARDS WD, KAUFMANN UP et al.: Differential histopathology of primary atheroscle-rotic and restenotic lesion from coronary arteries and saphenous vein bypass grafts in tissue obtained from 73 patients by percutaneous coronary atherectomy. Am. Coll Cardiol (1991) 17:442–448.
   PubMed Web of Science ®Google Scholar
• GARRATT KN, HOLMES DR, JR., BELL MR et al.: Morpho-logical studies: restenosis after directional atherec-tomy: differences between primary atheromatous and restenotic lesions and influence of subintimal tissue rejection. j Am. Coll. Cardiol. (1990) 16:1665–1671.
   Google Scholar
• OATES JA, FITZGERAL GA, BRANCH RA et al.: Clinical implications of prostaglandin and thromboxane A2 formation. N Engl. J Med. (1988) 319:689–699.
   PubMed Web of Science ®Google Scholar
• WALKER LN, BOWEN-POPE DF, ROSS R et al.: production of platelet-derived growth factor-like molecules by cultured arterial smooth muscle cells accompanies proliferation after arterial injury. Proc. Nati Acad. Sci. USA (1986) 83:7311–7315.
   PubMed Web of Science ®Google Scholar
• EPSTEIN SE, SPIER E, UNGER EF et al.: The basis ofmolecular strategies for treating coronary restenosis after angioplasty. J. Am. Coll. Cardiol. (1994) 23:1278–1288.
   PubMed Web of Science ®Google Scholar
• LIU MW, ROUBIN GS, KING SB III: Restenosis aftercoronary angioplasty: Potential biological determi-nants and role of in tim al hyp erplasia. Circulation (1989) 79:1374–1387.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ L, BOURASSA MG, LESPERANCE J et al.: Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl. J. Med. (1988) 318:1714–1719.
   PubMed Web of Science ®Google Scholar
• FAXON DP, SANBORN TA, HAUDENSCHILD CC et al.: Effect of antiplatelet therapy on restenosis after experimental angioplasty. Am. J. Cardiol. (1984) 53:72C–76C.
   Google Scholar
• LEMBO NJ, BKACK AJ, ROUBIN GS et al.: Effect ofpretreatment with aspirin versus aspirin and dipyri-damole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am. J. Cardiol (1990) 65:422–426.
   PubMed Web of Science ®Google Scholar
• SERRUYS PW, RUTSCH W, HEYNDRICKX GR et al.: Prevention of restenosis after percutaneous translu-minal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT). Circulation (1991) 84:1568–1580.
   Google Scholar
• SAVAGE MP, GOLDBERG S, MACDONALD RG et al.: Multi-hospital Eastern Atlantic Restenosis Trial II: A placebo controlled trial of thromboxane blockade in the prevention of restenosis following angioplasty. Am. Heart J. (1991) 122:1239–1244.
   PubMed Web of Science ®Google Scholar
• SCHROR K, WEBER AA: Roles of vasodilatory prosta-glandins in mitogenesis of vascular smooth muscle cells. Agents Actions Suppl. (1997) 4 8 :63–91.
   Google Scholar
• GERSHLICK AH, SPRIGGINS D, DAVIES SW et al.: Failureof epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomized placebo controlled trial. Br. Heart J (1994) 71:7–15.
   PubMedGoogle Scholar
• DARIOUS H, NIXDORFF U, ZANDER J, RUPPRECHT HJ, ERBEL R, MEYER J: Effects of ciprostene on restenosis rate during therapeutic transluminal angioplasty. Agents Actions Suppl. (1992) 37:305–311.
   PubMedGoogle Scholar
• SHARIS PJ, CANNON CP, LOSCALZO J: The antiplatelet effects of ticlopidine and clopidogrel. Ann. Intern. Med. (1998) 129:394–405.
   PubMed Web of Science ®Google Scholar
• KASTRATI A, SCHUHLEN H, HAUSLEITER J et al.: Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy. Six-month angiographic follow-up of the intracoronary stenting and an tithr omb o tic regimen (ISAR) Trial. Circulation (1997) 96:462–467.
   Google Scholar
• MUKHERJEE, REGINELLI JP, CHEW DP et al.: A potentialnew indication for thienopyridine ADP-receptor antagonists: In-stent restenosis. j Am. Coll. Cardiol (2000) 35:84A.
   Web of Science ®Google Scholar
• INIGUEZ RA, MACAYA MC, HERNANDEZ AR et al.: Theeffects of ticlopidine administration at low doses on the incidence of restenosis following percutaneous coronary angioplasty. Rev. Espan. Cardiol. (1991) 44:366–374.
   PubMedGoogle Scholar
• GAWAZ M, NEUMANN FJ, MAY A et al.: Changes inmembrane glycoproteins of circulating platelets after coronary stent implantation. Heart (1996) 76:166–172.
   PubMed Web of Science ®Google Scholar
• BITTL JA: Coronary stent occlusion: thrombushorribilis. J. Am. Coll. Cardiol. (1996) 28:368–370.
   PubMed Web of Science ®Google Scholar
• NEUMANN F-J, GAWAZ M, OTT I et al: Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. Am. Coll. Cardiol (1996) 27:15–21.
   PubMed Web of Science ®Google Scholar
• COLLER BS: GPII13/Illa antagonists: pathophysiologic and therapeutic insights from studies of C7E3 Fab. Thromb. Haemost. (1997) 26:285–293.
   Google Scholar
• GIBBLER WB, WILCOX RG, BODE C et al.: Prospective use of glycoprotein IIbillIa receptor blockers in the emergency department setting. Ann. Em erg. Med. (1998) 32:712–722.
   PubMed Web of Science ®Google Scholar
• O'SHEA C, TCHENG JE: Platelet glycoprotein integrin inhibition in acute myocardial infarction. J Invas. Cardiol. (1999) 11:494–499.
   PubMed Web of Science ®Google Scholar
• VORCHHEIMER DA, BADIMON JJ, FUSTER V: Platelet glycoprotein IIbillIa receptor antagonists in cardio-vascular disease. JAMA (1999) 281:1407–1414.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, CALIFF RM, WEISMAN HF et al (FOR THE EPIC INVESTIGATORS): Randomized trial of coronary intervention with antibody against platelet IIbillIa integrin for reduction of clinical restenosis: results at six months. Lancet (1994) 3 43:881–886.
   Google Scholar
• TOPOL EJ, FERGUSON JJ, WEISMAN HE et al. (FOR THE EPIC INVESTIGATOR GROUP): long-term protection from myocardial ischemic events in a randomized trial of brief integrin 133 blockade with percutaneous coronary intervention. JAMA (1997) 278:479–484.
   PubMed Web of Science ®Google Scholar
• LEFKOVITS J, PLOW EF, TOPOL EJ: Platelet glycoprotein IIbillIa receptors in cardiovascular medicine. N Engl. J. Med. (1995) 332:1553–1559.
   PubMed Web of Science ®Google Scholar
• THE EPILOG INVESTIGATORS: Platelet glycoprotein Db/DIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl. J. Med. (1997) 336:1689–1696.
   PubMed Web of Science ®Google Scholar
• THE CAPTURE INVESTIGATORS: Randomized-placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet (1997) 3 49 :1429–1435.
   Google Scholar
• THE ERASER INVESTIGATORS: Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER Study). Circulation (1999) 100:799–806.
   PubMed Web of Science ®Google Scholar
• NEUMANN F-J, KASTRATI A, SCHMITT C et al.: Effect of glycoprotein Hb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. j Am. Coll. Cardiol. (2000) 35:915–921.
   PubMed Web of Science ®Google Scholar
• THE EPISTENT INVESTIGATORS: Randomized placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIbillIa blockade. Lancet (1998) 352:87–92.
   PubMed Web of Science ®Google Scholar
• LINCOFF AM, CALIFF RM, MOLITERNO DJ et al. (FOR THE EPISTENT INVESTIGATORS): Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIbillIa receptors. N Engl. J. Med. (1999) 341:319–327.
   PubMed Web of Science ®Google Scholar
• MARSO SP, LINCOFF AM, ELLIS SG et al. (FOR THEEPISTENT INVESTIGATORS): Optimizing the percuta-neous interventional outcomes for patients with diabetes mellitus. Results of the EPISTENT (Evaluation of Platelet IIbillIa inhibitor for stenting trial) diabetic substudy. Circulation (1999) 100:2477–2484.
   Google Scholar
• CLOWES AW, CLOWES MM: Inhibition of smooth muscle cell proliferation by heparin molecules. Transplant. Proc. (1989) 21 :3700–3701.
   PubMed Web of Science ®Google Scholar
• MAJESKY MW, SCHWARTZ SM, CLOWES MM, CLOWES AW: Heparin regulates smooth muscle S phase entry in the injured rat carotid artery. Circ. Res. (1987) 61:296–300.
   PubMed Web of Science ®Google Scholar
• ELLIS SG, ROUBIN GS, WILENTZ J et al: Effects of 18-24hour heparin administration for prevention of restenosis after uncomplicated angioplasty. Am. Heart J (1989) 117:777–782.
   PubMed Web of Science ®Google Scholar
• WILENSKY RL, TANGUAY JF, ITO S et al.: Heparininfusion prior to stenting (HIPS) trial: Mnal results of a prospective, randomized, controlled trial evaluating the effects of local vascular delivery on intimal hyperplasia. Am. Heart J. (2000) 139:1061–1070.
   PubMed Web of Science ®Google Scholar
• BRACK MJ, CHAUHAN A, FOX J et al.: The SubcutaneousHeparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfraction-ated heparin on angiographic restenosis and clinical outcome. J. Am. Coll Cardiol (1995) 26:947–954.
   Google Scholar
• HARENBERG J, WUERZNER B, ZIMMERMANN R: Bio avail-abilityand antagonization of the low molecular weight heparin CY216 in man. Thromb. Res. (1986) 44:549–554.
   PubMed Web of Science ®Google Scholar
• HERBERT JM, MAFFRAND JP: Heparin interactions withcultured human vascular endothelial and smooth muscle cells: incidence on vascular smooth muscle cell proliferation. J Cell Physiol. (1989) 138:424–432.
   PubMed Web of Science ®Google Scholar
• FAXON DP, SPIRO TE, MINOR S et al.: LOW molecularweight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. Circulation (1994) 90:908–914.
   Google Scholar
• CAIRNS JA, GILL G, MORTON B et al.: Fish oils andlow-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal angioplasty. The EMPAR Study. Circulation (1996) 94:1553–1560.
   PubMed Web of Science ®Google Scholar
• KARSCH KP, PREISACK MB, BAILDON R et al (ON BEHALFOF THE REDUCE TRIAL GROUP): low-molecular-weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: results of a randomized, double-blind, unfractionated heparin and placebo - controlled, multicenter trial (REDUCE). j Am. Coll Cardiol. (1996) 28:1437–1443.
   PubMed Web of Science ®Google Scholar
• LABLANCHE J-M, MCFADDEN EP, MENEVEAU N et al.:Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty. The FACT Study. Circulation (1997) 96:3396–3402.
   PubMed Web of Science ®Google Scholar
• KIESZ RS, BUSZMAN P, MARTIN JL et al.: local delivery of enoxaparin to decrease restenosis after stenting: The POLONIA Study. Circulation (1999) 100:1–468.
   Google Scholar
• FAGAR G: Thrombin and proliferation of vascular smooth muscle cells. Circ. Res. (1995) 77:645–650.
   PubMed Web of Science ®Google Scholar
• GALLO R, PADUREAN A, TOSCHI V et al.: Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries. Circulation (1998) 97:581–588.
   PubMed Web of Science ®Google Scholar
• THOME LM, GIMPLE LW, BACHHUBER BG et al.: Early plus delayed hirudin reduces restenosis in the athero-sclerotic rabbit more than early administration alone. Potential implications for dosing of antithrombin agents. Circulation (1998) 98:2301–2306.
   Google Scholar
• SERRUYS PW, HERRMAN JP, SIMON R et al.: Acomparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl. J. Med. (1995) 333:757–763.
   PubMed Web of Science ®Google Scholar
• BITTL JA, STRONY J, BRINKER JA et al.: Treatment withbivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or post infarction angina. Hirulog Angioplasty Study Investi-gators. N Engl. J. Med. (1995) 333:764–769.
   PubMed Web of Science ®Google Scholar
• BURCHENAL JEB, MARKS DS, MANN T et al.: Effect ofdirect thrombin inhibition with bivalirudin (Hirulog) after coronary angioplasty. Am. J. CardioL (1995) 82 :511–515.
   Google Scholar
• JORDAN MA, TORSO RJ, THROWER D, WILSON L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Nad. Acad. ScL USA (1993) 90:9552–9556.
   PubMed Web of Science ®Google Scholar
• ROWINSKY EK, DONEHOWER RC: Paclitax el (Taxol). N Engl. J. Med. (1995) 332:1004–1014.
   PubMed Web of Science ®Google Scholar
• STRAUBINGER RM, SHARMA A, MURRAY M, MAYHEW E: Novel tax ol formulations: tax ol-containing liposomes. Monogr. Natl. Cancer Inst. (1993) 15:69–78.
   PubMedGoogle Scholar
• SOLLOT SJ, CHENGL, PAULEY RR et al.: Taxol inhibitsneointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin. Invest. (1995) 95:1869–1876.
   PubMed Web of Science ®Google Scholar
• HERDEG C, OBERHOFF M, BAUMBACH A et al.: localpaclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J. Am. Coll. Cardiol (2000) 35:1969–1976.
   PubMed Web of Science ®Google Scholar
• OBERHOFF M, CETIN S, AL GHOBAINY R et al.: localdelivery of paclitaxel before stent implantation in a porcine restenosis model. Eur. Heart J. (1999) 20 (Suppl.):511.
   Google Scholar
• BORNFELDT KE, ARNQUIST JH: Proliferation of vascularsmooth muscle cells and regulation by insulin-like growth Factor I and insulin. Diabetologia (1992) 35:104–108.
   PubMed Web of Science ®Google Scholar
• FOEGH M, KHIRABADI B, CHAMBERS E et al.: Inhibitionof coronary artery transplant atherosclerosis in rabbits with angiopeptin, an octapeptide. Atheroscle-rosis (1989) 78:229–236.
   PubMed Web of Science ®Google Scholar
• LIGHT JT, BELLAU JA, CHEN IL et al.: Angiopeptin enhances acetylcholine-induced relaxation and inhibits hyperplasia after vascular injury. Am. J Physiol. (1993) 265:H1265–1274.
   PubMed Web of Science ®Google Scholar
• HOWELL M, ORSKOV H, FRYSTYK F et al.: lanreotide, a somatostatin analogue, reduces insulin-like growth Factor I accumulation in proliferating aortic tissue in rabbits in vivo. Eur. j Endocrinol. (1994) 130:422–425.
   PubMed Web of Science ®Google Scholar
• HONG MK, KENT KM, MEHRAN R et al.: Continuoussubcutaneous angiopeptin treatment significantly reduces neointimal hyperplasia in a porcine coronary in-stent restenosis model. Circulation (1997) 95:449–454.
   PubMed Web of Science ®Google Scholar
• KENT KM, WILLIAMS DO, CASSAGNEAU B et al.: double-blind, controlled trial of the effect of angiopeptin on coronary restenosis following balloon angioplasty. Circulation (1993) 88 (Suppl. I) :1–506.
   Google Scholar
• EMANUELSSON H, BEATT KJ, BAGGER J-P et al. (FOR THE EUROPEAN ANGIOPEPTIN STUDY GROUP): long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. Circulation (1995) 91:1689–1696.
   Google Scholar
• ERIKSEN UH, AMTORP 0, BAGGER JP et al.: Randomizeddouble-blind Scandinavian trial of angiopep tin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty. Am. Heart J. (1995) 130:1–8.
   Google Scholar
• VON ESSEN R, OSTERMAIER R, GRUBE E et al: Effects ofoctreotide treatment on restenosis after coronary angioplasty: results of the VERAS study. Circulation (1997) 96:1482–1487.
   PubMed Web of Science ®Google Scholar
• MIYAZAWA K, KIKUCHI S, FUKUYAMA J et al.: Inhibitionof PDGF- and TGF-Beta 1 -induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells form spontaneously hyperten-sive rats. Atherosclerosis (1995) 118:213–221.
   PubMed Web of Science ®Google Scholar
• KOSUGA K, TAMAI H, UEDA K et al.: Effectiveness oftranilast on restenosis after directional coronary atherectomy. Am. Heart J. (1997) 1 3 4:712–718.
   Google Scholar
• ISHIWATA S, VERHEYE S, ROBINSON KA etal.: Inhibitionof neointima formation by tranilast in pig coronary arteries after balloon angioplasty and stent implanta-tion. J. Am. Coll. Cardiol. (2000) 35:1331–1337.
   Google Scholar
• GALLO R, PADUREAN A, JAYARAMAN T eta].: Inhibitionof intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation (1999) 99:2164–2170.
   Google Scholar
• BURKE SE, LUBBERS NL, CHEN YN et al.: Neointimalformation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. Cardiovasc. Pharmacol. (1999) 33:829–835.
   PubMed Web of Science ®Google Scholar
• KIMURA Y, TANI T, KANBE T eta].: Effect of cilostazol onplatelet aggregation and experimental thrombosis. Arzneim-Forshung/Drug Res. (1985) 35:1144–1149.
   Google Scholar
• TAKAHASHI S, OIDA K, FUJIWARA R et al.: Effect ofcilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J. Cardiovasc. Pharmacol. (1992) 20:900–906.
   PubMed Web of Science ®Google Scholar
• TSUCHIKANE E, KATOH 0, SUMITSUJI S et al.: Impact ofcilostazol on intimal proliferation after directional coronary atherectomy. Am. HeartJ (1998)135:495–502.
   Google Scholar
• TSUCHIKANE E, FUKUHARA A, KOBAYASHI T et al: Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation (1999) 100:21–26.
   PubMed Web of Science ®Google Scholar
• PARK S-W, LEE CW, HONG M-K et al.: Effect of cilostazol treatment on angiographic restenosis after coronary stent placement. Circulation (1999) 1 0 0 (Suppl. I):1–308.
   Google Scholar
• TIELL ML, SUSSMANN I, GORDON PB et al.: Suppression of fibroblast in vitro and of neointimal hyperplasia in vivo by triazolopyrimidine, trapidil. Artery (1983) 12:33–50.
   PubMedGoogle Scholar
• LIU MW, ROUBIN GS, ROBINSON KA et al.: Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation (1990) 81:1089–1093.
   PubMed Web of Science ®Google Scholar
• OKAMOTO S, INDEN M, SETSUDA M et al.: Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am. Heart J. (1992) 123:1439–1444.
   PubMed Web of Science ®Google Scholar
• MARESTA A, BALDUCELLI M, CANTINI L et al.: Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Circulation (1994) 90:2710–2715.
   PubMed Web of Science ®Google Scholar
• GALASSI AR, TAMBURINO C, NICOSIA A et al.: A r andom-ized trial of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, versus aspirin in prevention of angiographic restenosis after coronary artery Palmaz-Schatz stent implantation. Cathet. Cardiovasc. Intervent. (1999) 46:162–168.
   PubMed Web of Science ®Google Scholar
• CONSTANTINESCU DE, BANKA VS, TULENKO TN: lovastatin inhibits proliferation of arterial smooth muscle and endothelial cells. Indication in atheroscle-rosis and prevention of restenosis. Eur. Heart J. (1992) 13:82. Abstract.
   Google Scholar
• JUKEMA JW, BRUSHKE AV, VAN BOVEN AJ et al.: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation (1995) 91:2528–2540.
   Google Scholar
• SAHNI R, MANIET AR, VOGI G et al.: Prevention of restenosis by lovastatin after successful coronary angioplasty. Am. Heart J. (1991) 121:1600–1608.
   PubMed Web of Science ®Google Scholar
• WEINTRAUB WS, BOCCUZZI SJ, KLEIN L et al. (FOR THE LOVASTATIN RESTENOSIS TRIAL STUDY GROUP): lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl. J. Med. (1994) 331:1331–1337.
   PubMed Web of Science ®Google Scholar
• EMANUELSSON H, BEATT KJ, BAGGER J-P, THE LOVASTATIN RESTENOSIS TRIAL GROUP: long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. Circulation (1995) 91:1689–1696.
   Google Scholar
• BERTRAND ME, MCFADDEN EP, FRUCHART J-C et al. (FOR THE PREDICT TRIAL INVESTIGATORS): Effect of pravas-tatin on angiographic restenosis after coronary balloon angioplasty. J. Am. Coll. Cardiol. (1997) 30:863–869.
   PubMed Web of Science ®Google Scholar
• SERRUYS PW, FOLEY DP, JACKSON G et al. (ON BEHALF OF THE FLARE STUDY GROUP): A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty. Eur. Heart J. (1999) 20:58–69.
   PubMed Web of Science ®Google Scholar
• WALTER DH, SCHACHINGER V, ELSNER M et al.: Effect of statin therapy on restenosis after coronary stent implantation. Am. J Cardiol. (2000) 85:962–968.
   PubMed Web of Science ®Google Scholar
• CAREW TE, SCHWENKE DC, STEINBERG D: Antiathero-genic effect of probucol unrelated to its hyp ercholes-terolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degrada-tion in macrophage-rich fatty streaks slowing the progression of atherosclerosis in WHHL rabbit. Proc. Nati Acad. Sci. USA (1987) 84:7725–7729.
   PubMed Web of Science ®Google Scholar
• LIBBY P, GANZ P: Restenosis revisited - new targets, new therapies. N Engl. J. Med. J. (1997) 337:418–419.
   PubMed Web of Science ®Google Scholar
• TARDIFF J-C, COTE G, LESPERANCE J et al. (FOR THE MULTIVITAMINS AND PROBUCOL STUDY GROUP): Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl. J Med. (1997) 337:365–372.
   PubMed Web of Science ®Google Scholar
• YOKOI H, DAIDA H, KUVVABARA Y et al.: Effectiveness of an antioxidant in preventing restenosis after percuta-neous transluminal coronary balloon angioplasty: the Probucol Angioplasty Restenosis Trial. j Am. Coll. Cardiol. (1997) 30:855–862.
   PubMed Web of Science ®Google Scholar
• RODES J, COTE G, LESPERANCE J et al.: Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation (1998) 97:429–436.
   PubMed Web of Science ®Google Scholar
• SETSUDA M, INDEN M, HIRAOKA N et al.: Probucol therapy in the prevention of restenosis after percuta-neous transluminal coronary angioplasty. Clin. Ther. (1993) 15:374–382.
   PubMed Web of Science ®Google Scholar
• WATANABE K, SEKIYA M, IKEDA S et al.: Preventive effect of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am. Heart J. (1996) 132:23–29.
   PubMed Web of Science ®Google Scholar
• SEKIYA M, FUNADA J, WATANABE K et al.: Effects of probucol and cilostazol alone an in combination on frequency of poststenting restenosis. Am. J Cardiol (1998) 82:144–147.
   PubMed Web of Science ®Google Scholar
• POWELL JS, MULLER RKM, BAUMGARTNER HR et al.: Suppression of the vascular response to injury: the role of angiotensin converting enzyme inhibitors. J Am. Coll. Cardiol. (1991) 17:137B–142B.
   Google Scholar
• BROZOVICH FV, MORGANROTH J, GOTTLIEB NB et al.: Effect of angiotensin converting enzyme inhibition on the incidence of restenosis after percutaneous transluminal coronary angioplasty. Cath. Cardiovasc. Diag. (1991) 23:263–267.
   PubMedGoogle Scholar
• MULTICENTER EUROPEAN RESEARCH TRIAL WITH CILAZAPRIL AFTER ANGIOPLASTY TO PREVENT TRANSLUMINAL CORONARY OBSTRUCTION AND RESTENOSIS (MERCATOR) STUDY GROUP: Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR Study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation (1992) 86:100–110.
   PubMed Web of Science ®Google Scholar
• FAXON PD: Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo controlled trial of cilazapril. The Multicenter American Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J. Am. Coll. Cardiol. (1995) 25:362–369.
   Google Scholar
• DESMET W, VROLIX M, DESCHEERDER I et al.: Angiotensin converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty. Circulation (1994) 89:385–392.
   PubMed Web of Science ®Google Scholar
• KAUL U, CHANDRA S, BAHL VK et al.: Enalapril for the prevention of restenosis after coronary angioplasty. Indian Heart J. (1993) 45:469–473.
   PubMedGoogle Scholar
• KONDO J, SONE T, TSUBOI H et al.: The effect of quinapril on prevention of restenosis after coronary stenting were influenced by the insertion/deletion polymorphism in the angiotensin I-converting enzyme. Circulation (1999) 100 (Suppl. I) :1–467.
   Google Scholar
• ASSENDER JW, SOUTHGATE KM, NEWBY AC: Does nitric oxide inhibit smooth muscle proliferation? J. Cardio-vasc. Pharmacol. (1991) 17 (Suppl. 3):S104–5107.
   Google Scholar
• KIKICHI K, HIRATA M, NAGAOKA A et al.: Cardiovascular actions of mesoionic compounds, 3-substituted sydnonimines. Jpn. j Pharmacol. (1970) 20:23–43.
   PubMedGoogle Scholar
• LABLANCHE J-M, GROLLIER G, LUSSON J-R et al.: Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD Study. Circulation (1997) 95:83–89.
   PubMed Web of Science ®Google Scholar
• VON DER LEYEN HE, MUHS A, SCHRADER J et al.: Inhibi-tion on in-stent plaque formation by inducible nitric oxide synthetase-lipoplex-mediated gene therapy in a pig femoral artery stent model. J. Am. Coll. Cardiol. (2000) 33 (Suppl. A):280A.
   Google Scholar
• TURUNEN MP, HILTUNEN MO, YLA-HERTTUALA S: Gene therapy for angiogenesis, restenosis and related diseases. Exp. Gerontol. (1999) 34:567–574.
   PubMed Web of Science ®Google Scholar
• MULLER DW: The role of proto-oncogenes in coronary restenosis. Prog. Cardiovasc. Dis. (1997) 40:117–128.
   PubMed Web of Science ®Google Scholar
• SCHEINMAN M, ASCHER E, LEVI GS et al.: p53 gene transfer to the injured rat carotid artery decreases neointimal formation. j Vasc. Surg. (1999) 360:360–369.
   Google Scholar
• SHI Y, GALEO A, HUTCHINSON HG et al.: Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation (1994) 90:944–951.
   PubMed Web of Science ®Google Scholar
• AUTIERI MV, YUE TL, FERSTEIN GZ et al.: Antisense oligonucleotides to the p65 subunit of NF-KB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries. Biochem. Biophys. Res. Commun. (1995) 213:827–836.
   PubMed Web of Science ®Google Scholar
• STEPHAN D, SAN H, YANG ZY et al.: Inhibition of vascular smooth muscle cell proliferation and intimal hyperplasia by gene transfer of beta-interferon. Mot. Med. (1997) 9:593–599.
   Google Scholar
• HANNA AK, FOX JC, NESCHIS DG et al.: Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. j Vasc. Surg. (1997) 25:320–325.
   PubMed Web of Science ®Google Scholar
• KIBBE MR, BILLIAR TR, TZENG E: Gene therapy for restenosis. Circ. Res. (2000) 86:829–833.
   PubMed Web of Science ®Google Scholar
• LUO Z, SATA M, NGUYEN T, KAPLAN JM, AKITA GY, WALSH K: Adenovirus-Mediated Delivery of Fas Ligand Inhibits Intimal Hyperplasia After Balloon Injury in Immunologically Primed Animals. Circulation (1999) 99:1776–1779.
   PubMed Web of Science ®Google Scholar
• WAKSMAN R, ROBINSON KA, CROCKER IR et al.: Endovascular low-dose irradiation inhibits neointima formation after coronary artery balloon injury in swine. A possible role for radiation therapy in restenosis prevention. Circulation (1995) 91:1533–1539.
   Google Scholar
• WIEDERMANN JG, MARBOE C, AMOLS H et al.: intracoro-nary irradiation markedly reduces restenosis after balloon angioplasty in a porcine model. j Am. Coll Cardiol. (1994) 23:1491–1498.
   PubMed Web of Science ®Google Scholar
• HEHRLEIN C, GOLLAN C, DONGES K et al.: mw-dose radioactive endovascular stents prevent smooth cell proliferation and neointimal hyperplasia in rabbits. Circulation (1995) 92:1570–1575.
   PubMed Web of Science ®Google Scholar
• CONDADO JA, WAKSMAN R, GURDIEL 0 et al.: Long-term angiographic and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans. Circula-tion (1997) 96:727–32.
   Google Scholar
• TEIRSTEIN PS MASSULLO V, JANI S et al.: Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl. J. Med. (1997) 336:1697–1703.
   PubMed Web of Science ®Google Scholar
• TEIRSTEIN PS MASSULLO V, JANI S et al.: Three-year clinical and angiographic follow-up after intracoro-nary radiation. Circulation (2000) 101:360–365.
   PubMed Web of Science ®Google Scholar
• WAKSMAN R, WHITE L, CHAN RC et al.: Intracoronary 7-radiation after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation (2000) 101:2165–2171.
   PubMed Web of Science ®Google Scholar
• LEON MB, TEIRSTEIN PS, LANSKY AJ et al.: In tr aco r o n ar y gamma-radiation to reduce in-stent restenosis: the multicenter Gamma-I randomized clinical trial. j Am. Coll. Cardiol. (1999) 33 (Suppl. A):19A.
   Google Scholar
• GRUBERG L: Cardiovascular Radiation Therapy W. Int. Cardiovasc. Intervent. (2000) 3:55–59.
   Google Scholar
• KING SB III, WILLIAMS DO, CHOUGULE P et al.: Endovas-cular 13-radiation to reduce restenosis after coronary balloon angioplasty. Results of the Beta Energy Resteno sis Trial (BERT). Circulation (1998) 97:2025–2030.
   Google Scholar
• WAKSMAN R, BHARGAVA B, WHITE L et al.: Intracoro-nary 13-radiation therapy inhibits recurrence of in-stent restenosis. Circulation (2000) 101: 1895-1898.
   Google Scholar
• COSTA MA, SABATE M, VAN DER GIESSEN WJ et al: late coronary occlusion after in tr acoronary brachytherapy. Circulation (1999) 100:789–792.
   PubMed Web of Science ®Google Scholar
• ALBIERO R, ADAMIAN M, KOBAYASHI N et al.: Short and long-term results of 32P radioactive 13-emitting stent implantation in patients with coronary artery disease. The Milan Dose-Response Study. Circulation (2000) 101:18–26.
   PubMed Web of Science ®Google Scholar
• TAMAI H, IGAKI K, KYO E et al.: Initial and 6-month result of biodegradable poly-l-lactic acid coronary stents in humans. Circulation (2000) 102:399–404.
   PubMed Web of Science ®Google Scholar
• STEFANADIS C, DIAMANTOPOULOS L, TSIAMIS E et al.: External heating of stents reduces n coin tima formation after coronary stenting in pigs: a new promising method. Circulation (1999) 100 (Suppl. D:1–467.
   Google Scholar
• ROCKSON SG, LORENZ DP, CHEONG W-F et al.: Photoan-gioplasty. An emerging clinical cardiovascular role for photodynamic therapy. Circulation (2000)102:591–596.
   Google Scholar
• ALT E, HAEHNEL I, BEILHARZ C et al.: Inhibition of neointima formation after experimental coronary artery stenting: a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost. Circulation (2000) 1 01 :1453–1458.
   Google Scholar
• ZHENG H, BARRAGAN P, CORCOS T et al.: Clinical experience with a new biocompatible phosphorylcholine-coated coronary stent. J. Invasive Cardiol. (1999) 10:608–614.
   Google Scholar
• AHN YK, JEONG MH, KIM JW et al.: Preventive effects of the heparin-coated stent on restenosis in the porcine model. Catheter. Cardiovasc. Intern. (1999) 48:324–330.
   PubMed Web of Science ®Google Scholar